BNP Paribas Asset Management’s Cidara Therapeutics CDTX Stock Holding History

BNP Paribas Asset Management’s Portfolio CDTX Stock Details CDTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	–	Sell	-22,538	Closed	-$4.98M	–	2270
2025 Q4	$4.98M	Buy	+22,538	New	+$3.64M	0.01%	841

BNP Paribas Asset Management's CDTX Position: Q1 2026 in Review

BNP Paribas Asset Management sold out of Cidara Therapeutics (CDTX) in Q1 2026, closing a stake of 22,538 shares — an estimated $4.98M sold.

BNP Paribas Asset Management first reported a position in CDTX in Q4 2025 and held it in 1 quarter. The position peaked at $4.98M in Q4 2025. 0 funds tracked by Wall St. Rank hold CDTX as of Q1 2026.

BNP Paribas Asset Management reported no remaining Cidara Therapeutics position as of Q1 2026 after selling out during the quarter.
BNP Paribas Asset Management sold 22,538 Cidara Therapeutics shares in Q1 2026, an estimated $4.98M.
BNP Paribas Asset Management first reported a position in Cidara Therapeutics in Q4 2025 and held it in 1 quarter.
BNP Paribas Asset Management's Cidara Therapeutics position peaked at $4.98M in Q4 2025.
0 funds tracked by Wall St. Rank held Cidara Therapeutics as of Q1 2026.

Based on BNP Paribas Asset Management's 13F filing for Q1 2026, filed 14 May 2026.